Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia

Pediatric Transplantation

Volumn 17, Issue 4, 2013, Pages 387-393

  Chung, Nack Gyun ^a   Lee, Jae Wook ^a   Jang, Pil Sang ^a   Jeong, Dae Chul ^a   Cho, Bin ^a,b   Kim, Hack Ki ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

children; conditioning; cyclophosphamide; fludarabine; severe aplastic anemia

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; METHOTREXATE; MICAFUNGIN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; BLOOD DONOR; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; EMBOLISM; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT REJECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INCIDENCE; LIVER ABSCESS; MALE; MYCOSIS; NEURALGIA; NEUTROPHIL; OUTCOME ASSESSMENT; PNEUMONIA; PRESCHOOL CHILD; PROPHYLAXIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SIBLING; SURVIVAL RATE; TREATMENT DURATION; UNRELATED DONORS; VIRUS INFECTION; VOMITING;

ADOLESCENT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; NEUTROPHILS; RETROSPECTIVE STUDIES; SIBLINGS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE;

EID: 84878014788     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12073     Document Type: Article

References (25)

1. Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006: 12: 1277-1284.
2. Hsieh M-Y, Chiou T-J, Hung G-Y, Yen H-J,. Outcomes of matched sibling and alternative donor stem cell transplantation for 26 children with severe aplastic anemia. Int J Hematol 2010: 91: 54-60.
3. Samarasinghe S, Steward C, Hiwarkar P, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anemia following failure with immunosuppressive therapy: A United Kingdom multicentre retrospective experience. Br J Haematol 2012: 157: 339-346.
4. Perez-Albuerne ED, Eapen M, Klein J, et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol 2008: 141: 216-223.
5. Yagasaki H, Takahashi Y, Hama A, et al. Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia. Bone Marrow Transplant 2010: 45: 1508-1513.
6. Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA working party. Br J Haematol 1988: 70: 177-182.
7. Locasciulli A, van't Veer L, Bacigalupo A, et al. Treatment with marrow transplantation or immunosuppression of childhood acquired severe aplastic anemia: A report from the EBMT SAA Working Party. Bone Marrow Transplant 1990: 6: 211-217.
8. Führer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: A more severe disease predicts better survival. Blood 2005: 106: 2102-2104.
9. Jeong DC, Chung NG, Kang HJ, et al. Epidemiology and clinical long-term outcome of childhood aplastic anemia in Korea for 15 years: Retrospective study of the Korean Society of Pediatric Hematology Oncology (KSPHO). J Pediatr Hematol Oncol 2011: 33: 172-178.
10. Deeg HJ, Amylon MD, Harris RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: Minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001: 7: 208-215.
11. Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006: 108: 1485-1491.
12. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: A report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005: 36: 947-950.
13. George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M,. Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia. Pediatr Transplant 2008: 12: 14-19.
14. Bacigalupo A, Socie' G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: A retrospective study from the EBMT-SAA Working Party. Haematologica 2010: 95: 976-982.
15. Anderlini P, Acholonu SA, Okoroji GJ, et al. Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. Leuk Lymphoma 2011: 52: 137-141.
16. Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011: 118: 2351-2357.
17. Kang HJ, Shin HY, Park JE, et al. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multileft study. Biol Blood Marrow Transplant 2010: 16: 1582-1588.
18. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008: 46: 1813-1821.
19. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995: 15: 825-828.
20. Lee SJ, Vogelsang G, Flowers MED,. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003: 9: 215-233.
21. Tolar J, Deeg HJ, Arai S, et al. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: Early results of cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant 2012: 18: 1007-1011.
22. Yagasaki H, Takahashi Y, Kudo K, et al. Feasibility and results of bone marrow transplantation from an HLA-mismatched unrelated donor for children and young adults with acquired severe aplastic anemia. Int J Hematol 2007: 85: 437-442.
23. Yagasaki H, Kojima S, Yabe H, et al. Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia. Blood 2011: 118: 3186-3190.
24. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007: 110: 1397-1400.
25. Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood 2011: 118: 2618-2621.